PAR

6.98%

20.0¢ paradigm biopharmaceuticals limited..

Ann: PAR Selected for Major OA Conference Presentations, page-13

First 13 Last

Share
Profile

Follow
StevieBuoy

520 Posts.

322

30/01/24

13:41

Post #: 72134439
Share

Originally posted by PZ99: ↑

I’ve held PAR for about 10 years, buying at between 28c and $3, with an AEP of 80c or so. My total investment was around $50k.
I’ve written this off completely and nowadays hardly even bother to check the SP or read the threads.
I have no doubts at all about the efficacy of the product as both my wife and I have gained considerable symptomatic relief from OA, but as a company and as an ‘investment’ PAR imo falls somewhere between a lemon and a dog.
In my view we’re heading slowly and painfully straight down the gurgler.
Announcements such as these mean nothing at all really and like previous ones serve only to provide a bit of hope and sustenance to the remaining true believers (of which I’m no longer one).
What we have here imo is a company with a great product but with an average-at-best management team, a corporate governance model that falls short of best practice, and some fairly shaky IP.
I don’t believe in the prospect of a deal with ‘Big Pharma’ being just around the corner - if there was a deal to be done then imo it would have been done already.
Much more likely imo is more and more of the same thing; the company burning through its cash reserves while management draw big salaries, until we need yet another CR priced even lower than the last one.
At some point I think we’ll be delisted and whatever value remains will probably be picked up by some cashed up individuals ready to take a punt for a few cents on the dollar.
I’m fortunate enough to be fairly secure financially so the loss is more annoying for me than consequential, but others are in a very different position and to them I extend my sympathy. I only wish I’d got out when the SP was $4, as I don’t think we’ll ever see that again.
These are my personal thoughts and opinions only - don’t take them as any sort of advice, and GLTAH as always.

Expand

"with an average-at-best management team"

An extraordinary compliment to Paul Rennie and his team and one I think which is completely undeserved.

Paul, if you're reading this, do the right thing by the company and LEAVE. We'd be far better off without you. You should be ashamed of the mess you've overseen.

PAR Price at posting: 39.0¢ Sentiment: Buy Disclosure: Held
20 Upvote

9 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 23 more messages in this thread...

First 13 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.015(6.98%)		Mkt cap ! $70.04M

Open	High	Low	Value	Volume
21.0¢	21.0¢	20.0¢	$201.6K	994.6K

Buyers (Bids)

No.	Vol.	Price($)
15	429247	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	13806	2

View Market Depth

No.	Vol.	Price($)
12	389247	0.200
8	133607	0.195
17	238789	0.190
4	92160	0.185
8	122773	0.180

Price($)	Vol.	No.
0.210	13806	2
0.215	28509	1
0.220	59615	6
0.225	28604	2
0.230	16334	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PAR (ASX) Chart

Ann: PAR Selected for Major OA Conference Presentations, page-13

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: PAR Selected for Major OA Conference Presentations, page-13

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News